Doxorubicin (Doxo) and dacarbacin (DTIC) as first-line therapy for patients (pts) with locally advanced or metastatic leiomyosarcoma (LMS) and liposarcoma (LPS).
U. Bitz
No relevant relationships to disclose
D. Pink
No relevant relationships to disclose
C. Busemann
No relevant relationships to disclose
P. Reichardt
No relevant relationships to disclose